Scailyte AG
Scailyte AG is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Scailyte AG.
Scailyte AG is a company.
Key people at Scailyte AG.
Scailyte AG is a clinical-stage precision medicine company that develops diagnostic and companion diagnostic (CDx) solutions using its proprietary AI platform, ScaiVision, to analyze single-cell and multi-omics data for biomarker discovery in oncology, autoimmunity, and complex diseases like IBD and endometriosis.[2][3][6] It serves pharmaceutical companies, clinical partners, and patients by identifying ultra-sensitive biomarkers for patient stratification, treatment response prediction, and personalized therapies, solving the problem of imprecise treatments in hard-to-treat diseases through explainable AI-driven insights from high-dimensional cellular data.[1][2][5] The company shows strong growth momentum, with Series A extended to USD 8 million, asset divestment to Hera Biotech, pilots turning into multi-year pharma partnerships, CHF 12M+ in public funding, and positioning for a Series B targeting CHF 100M total contract value (TCV) by 2027.[1][4]
Founded in 2017 as a spin-off from ETH Zürich, Scailyte emerged from pioneering research in single-cell technologies, -omics analytics, and AI to uncover disease patterns that traditional methods miss.[2][3][5] The core idea stemmed from combining high-quality single-cell datasets (e.g., scRNA-seq, TCR-/BCR-seq) with machine learning to discover biomarkers, initially validated through Innosuisse grants for projects with University Hospital of Zürich and Inselspital Bern.[4] Early traction included ETH spin-off recognition, hiring key roles like Director of Biomarker Discovery and Senior Data Scientist, securing a first S&P 100 customer, and clinical validation of ScaiVision (patent pending).[4] Pivotal moments feature partnerships like Turnstone Bio for TIL therapy biomarkers, a UK diagnostics co-development, and recent leadership additions like Chief Business Officer Tim Foley in 2024 to expand into the US market.[2][4]
Scailyte rides the single-cell revolution in precision medicine, where AI meets multi-omics to unlock complex disease drivers amid surging demand for personalized therapies in oncology and autoimmunity.[1][2][6] Timing is ideal as single-cell tech enters clinical trials, with market forces like exploding omics data volumes (e.g., Tempus AI's model) and pharma's push for biomarkers favoring AI platforms that deliver 10x+ ROI via IP and partnerships.[1][4] It influences the ecosystem by divesting assets (e.g., to Hera Biotech), enabling TIL therapies (Turnstone), and scaling via grants/public funds, accelerating translation from research to diagnostics while setting standards for explainable AI in biotech.[4][8]
Scailyte is primed for Series B funding to expand its pharma business, negotiating LOIs with top players on IBD and beyond, projecting 5x-10x ROI through strategic acquisition by 2027.[1] Trends like multimodal data integration, AI explainability mandates, and US market entry (via new CBO) will propel its pipeline of diagnostics/CDx, potentially consolidating leadership in single-cell precision medicine.[2][6] As it scales from ETH spin-off to global player, Scailyte could redefine biomarker discovery, ensuring the right treatment reaches the right patient and transforming outcomes in untreatable diseases—echoing its mission to pioneer clinical impact from cellular insights.[2]
Key people at Scailyte AG.
